male androgenetic alopecia platelet-rich plasma, hair density, hair diameter, videodermoscopy
Conditions
Interventions
platelet-rich plasma prepared using a simple centrifuge tube was injected to one side of the scalp based on the assigned treatment group for a total of 3 sessions, each spaced four weeks apart.,platel
Experimental Device,Experimental Device
simple-tube centrifugation,commercial plasma separation system
Sponsors
Strategic Wisdom and Research Institute
Gibthai Company Limited Thailand
Eligibility
Sex/Gender
Male
Age
20 Years to 55 Years
Inclusion criteria
Inclusion criteria: 1.Male volunteers diagnosed with androgenetic alopecia at a mild to moderate severity (Norwood-Hamilton grade IIIv - V) 2. Have previously received standard medical treatment but were unable to continue or achieve effective results due to one of the following reasons: 2.1. Experienced side effects from standard treatment: 2.1.1. Finasteride: erectile dysfunction, decreased libido, depression, or gynecomastia. 2.1.2. Minoxidil: scalp irritation, contact dermatitis, or facial and periorbital edema. 2.2. Received standard treatment for more than 6 months without satisfactory response, such as no improvement in hair density or slowing of hair loss. 3. Aged 20 years or older. 4. Weigh 60 kilograms or more. 5. Able to attend follow-up appointments as scheduled. 6. Willingly consented to participate in the study by signing the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Having significant health problems, including: Cancer, heart disease, liver disease, kidney disease, lung disease, or hematologic disorders Hypertension, diabetes, thyroid disease, or HIV infection 2. Having abnormalities in platelet function, such as: Bleeding disorders Platelet dysfunction syndrome Platelet count <150,000 platelets per microliter (based on a complete blood count within 6 months prior to study enrollment) 3. History of using oral or injectable medications that affect hair growth within 6 months prior to study enrollment, including: Finasteride, dutasteride, minoxidil Spironolactone, cimetidine, diazoxide, cyclosporine, ketoconazole Corticosteroids, chemotherapeutic agents, vasodilators, and anticonvulsants 4. History of using topical medications, shampoos, or substances that affect hair growth within 1 to 6 months before enrollment, including: Topical dutasteride (within 6 months) Topical finasteride or minoxidil (within 3 months) Topical growth factors or stem cells (within 3 months) Ketoconazole shampoo (within 1 month) 5. History of other treatments for androgenetic alopecia within 6 months before enrollment, including: Low-level light or laser therapy PRP injection or topical PRP Microneedling, fractional lasers Intradermal injection of dutasteride or finasteride Injection of growth factors or stem cells 6. History of hair transplantation surgery 7. Presence of other medical conditions that can cause hair loss, such as trichotillomania 8. History of other scalp skin diseases, such as eczema, psoriasis, or tinea capitis 9. History of taking anticoagulants, thrombolytic agents, or nonsteroidal anti-inflammatory drugs (NSAIDs) within 2 weeks prior to study enrollment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hair density baseline,week 4, 8, 12, 24 after treatment videodermoscope (FotoFinder Leviacam) | — |
Secondary
| Measure | Time frame |
|---|---|
| Average Hair Diameter baseline,week 4, 8, 12, 24 after treatment videodermoscope (FotoFinder Leviacam),Adverse Events (e.g. Pain, Swelling, Headache, Erythema, Dry scalp) baseline,week 4, 8, 12, 24 after treatment Patient report ,Patient satisfaction 24 weeks after treatment global photography / 10-point visual analog scale ,overall clinical change 24 weeks after treatment Global Photography Assessment | — |
Countries
Thailand
Contacts
Public ContactSaranya Khunkhet
Department of Dermatology, Faculty of Medicine, Srinakharinwirot University
Outcome results
None listed